BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sheikh S, Alvi U, Soliven B, Rezania K. Drugs That Induce or Cause Deterioration of Myasthenia Gravis: An Update. J Clin Med 2021;10:1537. [PMID: 33917535 DOI: 10.3390/jcm10071537] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 17.0] [Reference Citation Analysis]
Number Citing Articles
1 Tugasworo D, Kurnianto A, Retnaningsih, Andhitara Y, Ardhini R, Budiman J. The relationship between myasthenia gravis and COVID-19: a systematic review. Egypt J Neurol Psychiatry Neurosurg 2022;58:83. [DOI: 10.1186/s41983-022-00516-3] [Reference Citation Analysis]
2 Grover KM, Sripathi N. Prevention of Adverse Outcomes and Treatment Side Effects in Patients with Neuromuscular Disorders. Semin Neurol 2022. [DOI: 10.1055/s-0042-1758779] [Reference Citation Analysis]
3 Reyes Fernandez PC, Wright CS, Warden SJ, Hum J, Farach-Carson MC, Thompson WR. Effects of Gabapentin and Pregabalin on Calcium Homeostasis: Implications for Physical Rehabilitation of Musculoskeletal Tissues. Curr Osteoporos Rep 2022. [PMID: 36149592 DOI: 10.1007/s11914-022-00750-x] [Reference Citation Analysis]
4 Zdraljevic M, Peric S, Jeremic M, Lavrnic D, Basta I, Hajdukovic L, Jovanovic DR, Berisavac I. Myasthenia gravis treated in the neurology intensive care unit: a 14-year single-centre experience. Neurol Sci 2022. [DOI: 10.1007/s10072-022-06379-z] [Reference Citation Analysis]
5 Dongre K, Jungo A, Späni S, Zysset Y, Leuppi-taegtmeyer A. Disease-Drug Interactions Requiring Special Attention. Praxis 2022;111:700-705. [DOI: 10.1024/1661-8157/a003923] [Reference Citation Analysis]
6 Haddad D, Hanna AJ, Russo L. Successful Neuromuscular Blockade Reversal Using Sugammadex and Neostigmine Failed to Prevent Myasthenic Crisis After Emergency Surgery: A Case Report. Cureus 2022. [DOI: 10.7759/cureus.27366] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Mahic M, Bozorg AM, DeCourcy JJ, Golden KJ, Gibson GA, Taylor CF, Ting A, Story TJ, Scowcroft A. Physician-Reported Perspectives on Myasthenia Gravis in the United States: A Real-World Survey. Neurol Ther 2022. [PMID: 35859033 DOI: 10.1007/s40120-022-00383-3] [Reference Citation Analysis]
8 Bhaskar S, Abdul Rani MFB, de Carvalho M. MuSK-Myasthenia Gravis Unmasked by Hydroxychloroquine. Case Reports in Medicine 2022;2022:1-4. [DOI: 10.1155/2022/4802538] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Huang C, Gao F, Zhou H, Zhang L, Shang D, Ji Y, Duan Z. Oral Microbiota Profile in a Group of Anti-AChR Antibody–Positive Myasthenia Gravis Patients. Front Neurol 2022;13:938360. [DOI: 10.3389/fneur.2022.938360] [Reference Citation Analysis]
10 Chang CK, Chien WC, Hsu WF, Chiao HY, Chung CH, Tzeng YS, Huang SW, Ou KL, Wang CC, Chen SJ, Wang DS. Positive Association Between Fluoroquinolone Exposure and Tendon Disorders: A Nationwide Population-Based Cohort Study in Taiwan. Front Pharmacol 2022;13:814333. [PMID: 35387340 DOI: 10.3389/fphar.2022.814333] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
11 Rodrigues CL, de Freitas HC, Lima PRO, de Oliveira Junior PH, Fernandes JMA, D'Almeida JAC, Nóbrega PR. Myasthenia gravis exacerbation and myasthenic crisis associated with COVID-19: case series and literature review. Neurol Sci 2022;43:2271-6. [PMID: 35039987 DOI: 10.1007/s10072-021-05823-w] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 7.0] [Reference Citation Analysis]
12 Zheng Y, Yuan X, Zhang C, Liu R, Jin H, Hao H, Li F, Zhao Y, Yuan Y, Wang Z, Gao F. Efficacy and Safety of Tacrolimus Therapy for a Single Chinese Cohort With Very-Late-Onset Myasthenia Gravis. Front Neurol 2022;13:843523. [DOI: 10.3389/fneur.2022.843523] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Alhaidar MK, Abumurad S, Soliven B, Rezania K. Current Treatment of Myasthenia Gravis. J Clin Med 2022;11:1597. [PMID: 35329925 DOI: 10.3390/jcm11061597] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
14 Pirwani N, Wrublik S, Ambati S. Myasthenia Gravis Masquerading as Status Asthmaticus. Case Rep Pediatr 2021;2021:6959701. [PMID: 34992892 DOI: 10.1155/2021/6959701] [Reference Citation Analysis]
15 Varlas V, Borş RG, Baroş A, Cîrstoiu MM, Frîncu F, Carp-velişcu A, Mehedinţu C. Myasthenia gravis in pregnancy – a multidisciplinary approach. Obstetrica şi Ginecologia 2022;2:18. [DOI: 10.26416/obsgin.70.2.2022.6675] [Reference Citation Analysis]
16 Wal A, Wal P, Pandey A, Vig H, Ved A, Samal HB. Overview of Myasthenia Gravis Subgroups and its influence on Pregnancy and their Treatment Advances. Pharmacophore 2022;13:19-30. [DOI: 10.51847/kvdmoxw5gj] [Reference Citation Analysis]
17 Abualkhair L, Almaghrabi A, Al Edrees N, Hassab Errasoul A. Unmasking of Myasthenia Gravis After Introduction of Oral Risperidone in a Schizophrenic Saudi Male: A Case Report. Cureus 2021. [DOI: 10.7759/cureus.20541] [Reference Citation Analysis]
18 Ziogas DC, Mandellos D, Theocharopoulos C, Lialios PP, Bouros S, Ascierto PA, Gogas H. Neuromuscular Complications of Targeted Anticancer Agents: Can Tyrosine Kinase Inhibitors Induce Myasthenia Gravis? Getting Answers From a Case Report up to a Systematic Review. Front Oncol 2021;11:727010. [PMID: 34722270 DOI: 10.3389/fonc.2021.727010] [Reference Citation Analysis]
19 Sivapurapu V, Natarajan P, Bhat R, Remadevi R. Myasthenia gravis and COVID-19 – A clinical checkmate. Anesth Essays Res 2021;15:457. [DOI: 10.4103/aer.aer_129_21] [Reference Citation Analysis]